Skip to content

Study · Not a test of the peptide alone · 1988

2 results

Human autoantibody to vasoactive intestinal peptide: increased incidence in muscular exercise.

Paul S, Said SI

Life sciences1 Jan 1988Cited by 14 (Europe PMC)

PMID3172975 (opens in a new tab)DOI10.1016/0024-3205(88)90203-2 (opens in a new tab)PepBankPUB-03172975
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyOther

    In healthy people, VIP autoantibodies were present in plasma of 29.6% of those who habitually exercised, versus 2.3% of those who did not.

    In plain wordsIn healthy people, antibodies against VIP were linked to regular exercise: found in 29.6% of exercisers and 2.3% of non-exercisers.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreasePrevalence of VIP autoantibodies in people who exercise
    Study

    n: not reported in source

    Comparator
    Healthy subjects who did not exercise
    Outcome group
    Immune response · Immune and inflammation

    Measurements

    prevalence of VIP autoantibodies
    29.6%
    habitual exercise
    prevalence of VIP autoantibodies
    2.3%
    no habitual exercise

    Source sentences

    Summary
    Specific autoantibodies to vasoactive intestinal peptide were present in plasma from 29.6% healthy human subjects who habitually performed muscular exercise, compared to 2.3% healthy subjects who did not.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneObservational studyActivity measurement

    In plasma of high-exercise subjects, the mean affinity constants (Ka) were 1.3 x 10(8) M-1 for the high affinity and 0.8 x 10(7) M-1 for the low affinity VIP autoantibody class.

    In plain wordsIn people who exercise a lot, antibodies against VIP fell into two classes that bound VIP with different strengths.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableAffinity constants of VIP autoantibody classes
    Study

    n: not reported in source

    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Saturation analysis of VIP binding by the plasmas suggested the presence of 1 and 2 classes of autoantibodies in 5 and 3 high exercise subjects, respectively, distinguished by their equilibrium affinity constants (Ka). The mean Ka values for the high and low affinity autoantibody classes were, respe…

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.